Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride

TurkeyIn the present study we aimed to demonstrate the efficacy of short-term pretreatment with finasteride in patients undergoing transurethral resection of the prostate (TUR-P). For this purpose 40 patients with BPH, who were candidates for TUR-P, were randomized into two groups. The first group (n ¼ 20) received 5 mg finasteride/day for 4 weeks prior to surgery and the second group (n ¼ 20) remained as the control. Patients who underwent prior prostate or urethral surgery and had a diagnosis of prostate cancer or chronic renal failure, patients who received finasteride, aspirin, coumadin or similar anticoagulant drugs prior to surgery and patients who had capsule perforations or open sinuses during the surgery were excluded from the study. All patients had a normal digital rectal examination and PSA values less than 4 ng/ml. As we look at the results there was no statistically significant difference between the finasteride group and control group regarding age, IPSS, PSA, prostate volumes, preoperative serum hemoglobin, hematocrit values and mean operating times and used irrigating fluids. The total amount of bleeding and bleeding per gram resected tissue were significantly lower in the finasteride group regardless of prostate volume. Furthermore the decrease in the hemoglobin and hematocrit values was higher in the control group. As a conclusion four weeks of finasteride pretreatment provided a significant decrease in peroperative bleeding regardless of prostate volume without any major side effects.

Section: Discussionmentioning

confidence: 99%

Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study

Ozdal

Özden

Benlı

et al. 2005

“…FGF-2 (bFGF) is synthesised by the prostatic stroma but is also located to a lesser extent within the epithelium, especially the basal cells. 8,10,13,15 FGF-2 is assumed to act in an autocrine fashion on the stroma causing a dose-dependent increase in its growth. 23 Increased levels of FGF-2 have been found in the stroma of prostates with BPH 13,14 coincident with an increased expression of its receptor FGFR1, 16 and its synthesis is considered to be under androgenic control.…”

Section: Discussionmentioning

confidence: 99%

“…7,[10][11][12][13][14][15][16] Insulin-like growth factor (IGF) isoforms have also been demonstrated within stromal cells 7,17 and are increased in elderly men 17 and in cases of BPH. 7 Transforming growth factor beta (TGF-b) isoforms are synthesised by the stroma and their receptors expressed by the epithelium.…”

Section: Introductionmentioning

confidence: 99%

Relationship between upregulated oestrogen receptors and expression of growth factors in cultured, human, prostatic stromal cells exposed to estradiol or dihydrotestosterone

Smith

Rhodes

et al. 2004

This study investigated the hypothesis that, in benign prostatic hyperplasia (BPH), upregulated oestrogen receptors (ER) and the action of androgens differentially regulate expression of stromal growth factors. Eight human prostatic stromal cell strains were subjected to a procedure to upregulate their ER by exposing them to 1 lmol 17b-estradiol for 10 days followed by passage and growth in the absence of steroids. Four of the cell strains instead received 100 nmol dihydrotestosterone for 48 h. Immunoexpression of ERa, AR and six growth factors was quantified by flow cytometry in each case. Expression of ERa was significantly increased in six of eight cell strains. Expressions of six growth factors (FGF-2, FGF-7, IGF-1, TGF-b 1 NGF and e NOS) were elevated but only for FGF-7 was it significant. There was a significant positive correlation between the change in ERa and the change in FGF-2 and FGF-7, but not the other growth factors. Exposure to dihydrotestosterone reduced expression of ERa and all six growth factors, compared with oestrogentreated cells but not significantly. It is concluded that upregulated ERa in prostatic stroma may have a greater modulating influence on synthesis of certain growth factors than the direct action of androgens and, by enhancing synthesis of FGF-2 and FGF-7, could play a significant role in the development of BPH.

“…14 This investigation then examines the interaction of different combinations of testosterone and 17b-estradiol on the immunoexpression of both AR and ER as well as fibroblast growth factors 7 2 and 7 7. FGF-2 (bFGF) has been shown by immunohistochemistry to be present in stromal cells 15,16 and is increased in BPH. 16,17 This peptide appears to stimulate growth of stromal cells in an autocrine manner.…”

Section: Introductionmentioning

confidence: 99%

“…FGF-2 (bFGF) has been shown by immunohistochemistry to be present in stromal cells 15,16 and is increased in BPH. 16,17 This peptide appears to stimulate growth of stromal cells in an autocrine manner. 17,18 FGF-7 (KGF), is produced exclusively by stromal cells.…”

Section: Introductionmentioning

confidence: 99%

Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol

Smith

Rhodes

et al. 2002

This study was performed to develop an experimental model in which expression of estrogen receptors (ER) by human prostatic stromal cells could be reproducibly enhanced relative to similar cells with low ER expression. The second aim was to characterise changes in expression of ER, androgen receptor (AR), FGF-2 and FGF-7 in stromal cells exposed to high and low concentrations of estradiol and testosterone mimicking the different sex hormone levels between young and elderly men. Five strains of human prostatic stromal cells, isolated from BPH resections, were grown in steroid-free medium plus 1 mmol 17b-estradiol. After 10 days, cells were passaged and grown in the same medium without estradiol until confluent. In a second study four cell strains were exposed to high and low concentrations of 17b-estradiol and testosterone for 10 days. Cells were labelled with fluorescent antibodies to ERa, AR, FGF-2 and FGF-7 and the fluorescence intensity measured by flow cytometry. Following exposure to 1 mmol estradiol, stromal cells showed reduced expression of AR and ERa but after passage without estradiol they showed a 25% increase in both receptors over controls. Different combinations of sex hormones induced inconsistent changes with respect to expression of ER, AR and FGFs in the various cell-strains. However, there was a highly significant correlation between AR, ER and FGF-2 and FGF-7, which was cell strain-specific. Thus, changes in sex hormone balance per se may not be solely responsible for the observed increases in prostatic ER levels in BPH. Since expression of ER is correlated with synthesis of FGF-2 and FGF-7, it is likely that increases in stromal ER may mediate the synthesis of stromallyderived growth factors which contribute to the aetiopathogenesis of benign prostatic hyperplasia.